Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, August 2, 2016

One Step Closer to First Human Use of DBS for Stroke Recovery - Cleveland Clinic

So instead of going for the easy and simple possibilities they are going for one of the moon shots. All because we have NO stroke leadership enforcing a realistic stroke strategy.
Maybe these 31 hyperacute options  in the first week.
https://consultqd.clevelandclinic.org/2016/07/one-step-closer-first-human-use-dbs-stroke-recovery/?
Cleveland Clinic is ready to begin the first human trial of deep brain stimulation (DBS) for post-stroke physical rehabilitation. So announced the trial’s leader, Andre Machado, MD, PhD, Chairman of Cleveland Clinic’s Neurological Institute, this week. The news follows Cleveland Clinic’s recent approval from the FDA to conduct the pioneering trial, as reported earlier this year on Consult QD.

Will promising rodent findings translate?

The go-ahead from the FDA came after 10 years of research by Dr. Machado and his team using a rodent model of stroke. That work showed that stimulation of a novel brain pathway promoted motor recovery along with neurogenesis and angiogenesis in the thalamus and perilesional cortex, as reported last year.
“Our findings suggested that DBS of the cerebello-thalamo-cortical pathway may enhance the brain’s plasticity and ability to form new neural connections during recovery from stroke,” says Dr. Machado, a neurosurgeon (shown in surgery in the photo above) who will perform the DBS procedures in the newly launched trial. “The expectation is that stimulation may augment the effects of physical rehabilitation for stroke.”
He notes that the cerebellum, which controls voluntary muscle movements, was part of the region targeted for stimulation in the hope of reestablishing flow of neurological input to the brain hemisphere affected by stroke.

An adjunct to rehab therapy

Candidates for the new trial will be ischemic stroke patients who suffered a stroke 12 to 24 months previously and have residual severe weakness affecting one arm despite treatment with physical therapy. Key questions the trial will seek to address include:
  • Who are the best candidates for DBS therapy, given the heterogeneity of stroke survivors?
  • At what point in post-stroke recovery would DBS be most beneficial?
  • Is continuous DBS needed, or do benefits endure without ongoing stimulation?
Dr. Machado notes that the goal of DBS in this setting is to augment, not replace, the effects of physical rehabilitation. “The proposition here is to make that recovery greater,” he told Time magazine in a new exclusive interview.
In the same interview he noted what most distinguishes this latest application of DBS from prior uses of the technology, such as for movement disorders: “The big difference is that when we are treating the motor symptoms of Parkinson’s disease, we’re trying to make the symptom, like a tremor, go away. When we are treating stroke, we are really trying to make movement come back. There is something inherently different about that.”

No comments:

Post a Comment